These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26435454)

  • 41. The role and therapeutic potential of melatonin in age-related ocular diseases.
    Crooke A; Huete-Toral F; Colligris B; Pintor J
    J Pineal Res; 2017 Sep; 63(2):. PubMed ID: 28658514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent overview of ocular patents.
    Gaudana RJ; Gokulgandhi MR; Boddu SH; Mitra AK
    Recent Pat Drug Deliv Formul; 2012 Aug; 6(2):95-106. PubMed ID: 22493994
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of ocular drug delivery systems using molecularly imprinted soft contact lenses.
    Tashakori-Sabzevar F; Mohajeri SA
    Drug Dev Ind Pharm; 2015 May; 41(5):703-13. PubMed ID: 25113431
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current nanotechnological strategies for treating glaucoma.
    Goyal G; Garg T; Rath G; Goyal AK
    Crit Rev Ther Drug Carrier Syst; 2014; 31(5):365-405. PubMed ID: 25271557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent advances in drug delivery systems for treating ocular complications of systemic diseases.
    Lee SS; Hughes PM; Robinson MR
    Curr Opin Ophthalmol; 2009 Nov; 20(6):511-9. PubMed ID: 19667987
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 2nd Ophthalmic Drug Development and Delivery Summit.
    Marra M; Gukasyan HJ; Raghava S; Kompella UB
    Expert Opin Drug Deliv; 2007 Jan; 4(1):77-85. PubMed ID: 17184164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.
    Fattal E; Bochot A
    Adv Drug Deliv Rev; 2006 Nov; 58(11):1203-23. PubMed ID: 17097190
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overview of age-related ocular conditions.
    Akpek EK; Smith RA
    Am J Manag Care; 2013 May; 19(5 Suppl):S67-75. PubMed ID: 23725498
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nanotechnology-based ocular drug delivery systems: recent advances and future prospects.
    Li S; Chen L; Fu Y
    J Nanobiotechnology; 2023 Jul; 21(1):232. PubMed ID: 37480102
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel drug delivery systems for retinal diseases. A review.
    Lee SS; Robinson MR
    Ophthalmic Res; 2009; 41(3):124-35. PubMed ID: 19321933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. What to expect at your eye exam.
    Randall HG
    Diabetes Self Manag; 2002; 19(4):8-10, 13-4. PubMed ID: 12533843
    [No Abstract]   [Full Text] [Related]  

  • 52. Iontophoresis: a non-invasive ocular drug delivery.
    Eljarrat-Binstock E; Domb AJ
    J Control Release; 2006 Feb; 110(3):479-89. PubMed ID: 16343678
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Challenges in neuroprotective nanomedicine development: progress towards noninvasive gene therapy of glaucoma.
    Alqawlaq S; Huzil JT; Ivanova MV; Foldvari M
    Nanomedicine (Lond); 2012 Jul; 7(7):1067-83. PubMed ID: 22846092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipid-based drug delivery systems in the treatment of wet age-related macular degeneration.
    Du JD; Fong WK; Caliph S; Boyd BJ
    Drug Deliv Transl Res; 2016 Dec; 6(6):781-792. PubMed ID: 27194165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protein Microarrays: Valuable Tools for Ocular Diseases Research.
    Garranzo-Asensio M; Montero-Calle A; Solís-Fernández G; Barderas R; Guzman-Aranguez A
    Curr Med Chem; 2020; 27(27):4549-4566. PubMed ID: 31244416
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.
    Short BG
    Toxicol Pathol; 2008 Jan; 36(1):49-62. PubMed ID: 18337221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Managed care implications of age-related ocular conditions.
    Cardarelli WJ; Smith RA
    Am J Manag Care; 2013 May; 19(5 Suppl):S85-91. PubMed ID: 23725500
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-Density Lipoprotein Cholesterol in Age-Related Ocular Diseases.
    Betzler BK; Rim TH; Sabanayagam C; Cheung CMG; Cheng CY
    Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32331355
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New Highlights of Resveratrol: A Review of Properties against Ocular Diseases.
    Delmas D; Cornebise C; Courtaut F; Xiao J; Aires V
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525499
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overview of biopolymers as carriers of antiphlogistic agents for treatment of diverse ocular inflammations.
    Sharma AK; Arya A; Sahoo PK; Majumdar DK
    Mater Sci Eng C Mater Biol Appl; 2016 Oct; 67():779-791. PubMed ID: 27287177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.